pioglitazone has been researched along with Malignant Melanoma in 4 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We observed that activation of PPARγ by its agonist, pioglitazone, reduces tumor volume, Tlr-4, Myd-88, Nf-kb1 mRNA expression, TLR4 protein expression and TNF-α production in melanoma tumor especially in groups that were injected with LPS -stimulated cells." | 7.91 | PPAR γ agonist, pioglitazone, suppresses melanoma cancer in mice by inhibiting TLR4 signaling. ( Dana, N; Haghjooy Javanmard, S; Vaseghi, G, 2019) |
| "A Phase II trial was initiated to analyze the activity of a continuously administered molecularly targeted treatment regimen (daily pioglitazone [45 mg administered orally] and rofecoxib [25 mg administered orally]) combined with sequentially added angiostatic chemotherapy for patients with previously treated metastatic melanoma (n = 19) or soft tissue sarcoma (n = 21)." | 7.72 | Pioglitazone and rofecoxib combined with angiostatically scheduled trofosfamide in the treatment of far-advanced melanoma and soft tissue sarcoma. ( Andreesen, R; Bataille, F; Berand, A; Bross, K; Krause, SW; Reichle, A; Vogt, T; Wild, P, 2004) |
| " Here, by employing syngeneic mouse colon cancer model and melanoma model, we studied the effects of 6 common antidiabetic drugs on anti-PD1 immune checkpoint inhibitor in tumor treatment, including acarbose, sitagliptin, metformin, glimepiride, pioglitazone, and insulin." | 4.12 | The Effects of 6 Common Antidiabetic Drugs on Anti-PD1 Immune Checkpoint Inhibitor in Tumor Treatment. ( Cheng, MZ; Gao, Y; Liu, L; Zhan, ZT; Zhou, WJ, 2022) |
| "We observed that activation of PPARγ by its agonist, pioglitazone, reduces tumor volume, Tlr-4, Myd-88, Nf-kb1 mRNA expression, TLR4 protein expression and TNF-α production in melanoma tumor especially in groups that were injected with LPS -stimulated cells." | 3.91 | PPAR γ agonist, pioglitazone, suppresses melanoma cancer in mice by inhibiting TLR4 signaling. ( Dana, N; Haghjooy Javanmard, S; Vaseghi, G, 2019) |
| "A Phase II trial was initiated to analyze the activity of a continuously administered molecularly targeted treatment regimen (daily pioglitazone [45 mg administered orally] and rofecoxib [25 mg administered orally]) combined with sequentially added angiostatic chemotherapy for patients with previously treated metastatic melanoma (n = 19) or soft tissue sarcoma (n = 21)." | 3.72 | Pioglitazone and rofecoxib combined with angiostatically scheduled trofosfamide in the treatment of far-advanced melanoma and soft tissue sarcoma. ( Andreesen, R; Bataille, F; Berand, A; Bross, K; Krause, SW; Reichle, A; Vogt, T; Wild, P, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhan, ZT | 1 |
| Liu, L | 1 |
| Cheng, MZ | 1 |
| Gao, Y | 1 |
| Zhou, WJ | 1 |
| Dana, N | 1 |
| Vaseghi, G | 1 |
| Haghjooy Javanmard, S | 1 |
| Reichle, A | 2 |
| Bross, K | 1 |
| Vogt, T | 2 |
| Bataille, F | 1 |
| Wild, P | 1 |
| Berand, A | 2 |
| Krause, SW | 1 |
| Andreesen, R | 2 |
| Coras, B | 1 |
| Terheyden, P | 1 |
| Neuber, K | 1 |
| Trefzer, U | 1 |
| Schultz, E | 1 |
| Bröcker, EB | 1 |
| Landthaler, M | 1 |
1 trial available for pioglitazone and Malignant Melanoma
| Article | Year |
|---|---|
Targeted combined anti-inflammatory and angiostatic therapy in advanced melanoma: a randomized phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Che | 2007 |
3 other studies available for pioglitazone and Malignant Melanoma
| Article | Year |
|---|---|
The Effects of 6 Common Antidiabetic Drugs on Anti-PD1 Immune Checkpoint Inhibitor in Tumor Treatment.
Topics: Acarbose; Animals; Hypoglycemic Agents; Immune Checkpoint Inhibitors; Insulin; Melanoma; Metformin; | 2022 |
PPAR γ agonist, pioglitazone, suppresses melanoma cancer in mice by inhibiting TLR4 signaling.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Drug Screening Assays, Antitumor; Male; Melanoma | 2019 |
Pioglitazone and rofecoxib combined with angiostatically scheduled trofosfamide in the treatment of far-advanced melanoma and soft tissue sarcoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemot | 2004 |